| Press releases

Formycon Announces Details of Further Pipeline Product: FYB202 is a Biosimilar Candidate for Stelara® (ustekinumab)

Formycon has announced details of a further product from its development pipeline: FYB202 is a biosimilar candidate for Stelara®* (ustekinumab).


Annual General Meeting

June 13, 2017; Munich/Germany

Financial reports

Annual Report 2016

Published on:
May 3, 2017

  • teaser-powerlist
  • teaser-wachstumschampion-en
  • Forschungssiegel_Teaser_Webseite-en
  • buchner_en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out.